News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Release: North American Phase III Trial With Grass Allergy Immunotherapy Tablet Meets Primary Endpoint, FDA Filing Remains Planned for 2013



10/23/2012 8:47:32 AM

Copenhagen, 2012-10-23 14:06 CEST (GLOBE NEWSWIRE) -- Merck initiated the trial in 2011 to evaluate the efficacy and safety of grass AIT versus placebo in the treatment of grass pollen induced allergic rhinoconjunctivitis (hay fever). The primary endpoint was the combined rhinoconjunctivitis daily symptom score (DSS) and rhinoconjunctivitis daily medication score (DMS) during the grass pollen season. The trial, which included approximately 1,500 patients, is the largest study of grass AIT to date.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES